Research programme: antibacterials - GlaxoSmithKline/FUJIFILM Toyama Chemical
Latest Information Update: 29 Oct 2018
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 13 Sep 2004 Preclinical trials in Bacterial infections in Japan (unspecified route)
- 13 Sep 2004 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)